Brain Cannabinoid CB2 Receptor in Schizophrenia

  title={Brain Cannabinoid CB2 Receptor in Schizophrenia},
  author={Hiroki Ishiguro and Yasue Horiuchi and Maya Ishikawa and Minori Koga and Keiko Imai and Yoshimi Suzuki and Miyuki Morikawa and Toshiya Inada and Yuichiro Watanabe and Makoto Takahashi and Toshiyuki Someya and Hiroshi Ujike and Nakao Iwata and Norio Ozaki and Emmanuel Shan Onaivi and Hiroshi Kunugi and Tsukasa Sasaki and Masanari Itokawa and Makoto Arai and Kazuhiro Niizato and Shyuji Iritani and Izumi Naka and Jun Ohashi and Akiyoshi Kakita and Hitoshi Takahashi and Hiroyuki Nawa and Tadao Arinami},
  journal={Biological Psychiatry},

Tables from this paper

Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia

The present findings reveal an imbalance in the expression and function of different elements of the endocannabinoid system in schizophrenia and emphasises its elements as potential targets in the search for new therapeutic strategies.

Deletion of CB2 Cannabinoid Receptor Induces Schizophrenia-Related Behaviors in Mice

The results suggest that deletion of CB2r has a relation with schizophrenia-like behaviors and Pharmacological manipulation ofCB2r may merit further study as a potential therapeutic target for the treatment of schizophrenia-related disorders.

Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits

The studies discussed below could suggest that CB2 receptors are anatomically located in schizophrenia-relevant circuits, where the physiological consequence of CB2 receptor activation could correct circuit-based deficits commonly associated with positive and cognitive deficits.

Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia

  • M. Fakhoury
  • Psychology, Medicine
    Molecular Neurobiology
  • 2016
A closer look will be given at the roles of the cannabinoid receptors type 1 and type 2 (CB2), as well as the endogenous ligand N-arachidonoylethanolamine (AEA) and 2-arACHidonylglycerol (2-AG), in the development of psychotic and schizophrenia-like symptoms.

Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders

Its non-psychoactive effect makes theCB2R a potential target for treating CNS disorders; however, a better understanding of the fundamental pharmacology of CB2R activation is essential for the design of novel therapeutic strategies.

Association of cannabinoid receptor genes (CNR1 and CNR2) polymorphisms and panic disorder

Polymorphisms at the CNR1 gene may be a risk factor for PD contributing to sex-specific dysfunction in females, with a significantly increased risk associated with the G-allele and C-allelles.

CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity

Current understanding of CNR2 genomic structure, its polymorphic nature, subtype specificity, from mice to human subjects, and its variants that confer vulnerabilities to neuropsychiatric disorders beyond neuro-immuno-cannabinoid activity are summarized.

New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders

Recent advances on the role of CB2Rs in neuropsychiatric and neurodegenerative disorders, including, but not limited to, anxiety, depression, schizophrenia, Parkinson's disease (PD), Alzheimer’s disease (AD), Huntington’S disease (HD) and addiction are addressed.



CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia

The present findings indicated that certain alleles or genotypes of the CNR1 gene may confer a susceptibility of schizophrenia, especially of the hebephrenic type.

Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia

Schizophrenic subjects with prominent lifetime scores for disorganization and negative symptoms (dimension for hebephrenia) are associated with the CNR1 gene and present a type of symptomatology that resembles chronic cannabinoid‐induced psychosis, which points to the possibility of different genetic and pathophysiologic mechanisms underlying different types of schizophrenia.

Brain Neuronal CB2 Cannabinoid Receptors in Drug Abuse and Depression: From Mice to Human Subjects

The functional expression of CB2-Rs in brain that may provide novel targets for the effects of cannabinoids in depression and substance abuse disorders beyond neuro-immunocannabinoid activity is demonstrated.

Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1.

The first report of an significant association between CB1 receptor and a subtype of schizophrenia is reported, with a borderline lack of allele g and a significant lack of gg genotype in the non-substance-abusing patients compared to substance-abused patients.

Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression

The data show that different medications have an impact on the expression of CB1 receptors in the ACC, and the human endogenous cannabinoid system is an appealing target in the investigation of psychiatric disorders.

Endocannabinoid signalling in the blood of patients with schizophrenia

Findings indicate that endocannabinoid signalling might be altered during the acute phase of schizophrenia not only in the central nervous system but also in the blood, related to the several immunological alterations described in schizophrenia.

(AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population

The results suggest that, independent of substance abuse, differences in the cannabinoid system function could be involved in the vulnerability to schizophrenia in Spanish population.

Discovery of the Presence and Functional Expression of Cannabinoid CB2 Receptors in Brain

It is demonstrated that CB2 CBrs and their gene transcripts are widely distributed in the brain, contrary to the prevailing view that CB 2 CBrs are restricted to peripheral tissues and predominantly in immune cells.

Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans

Alcohol preference in conjunction with chronic mild stress were enhanced in mice treated with CB2 agonist JWH015 when subjected to chronic stress, whereas antagonist AM630 prevented development of alcohol preference.

Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic Symptoms

The results suggest that anandamide elevation in acute paranoid schizophrenia may reflect a compensatory adaptation to the disease state, and the endocannabinoids are a family of bioactive lipids that activate CB1 cannabinoid receptors in the brain and exert intense emotional and cognitive effects.